In-Depth Analysis of the Gastric Cancer Market: Growth Opportunities, Key Trends, and Forecast 2025-2034

How Are the key drivers contributing to the expansion of the gastric cancer market?
The anticipated increase in obesity rates is likely to foster the expansion of the gastric cancer market. Obesity, a health condition marked by an accumulation of excess body fat, often identified by a body mass index (BMI) of 30 or above, can lead to numerous health issues. The escalation in obesity rates is driven by factors like unhealthy eating habits, physical inactivity, sedentary lifestyles, environmental factors, and genetic factors. Excessive body fat, especially the accumulated visceral fat around the belly, is associated with a higher gastric cancer risk as obesity initiates chronic inflammation and metabolic disorders, both linked to cancer propagation, leading to an increased need for gastric cancer treatment. For instance, as per the World Health Organization, a Switzerland-based IGO, approximately 1 in 8 people globally were obese in 2022, with 2.5 billion adults over 18 categorized as overweight, which includes 890 million individuals battling obesity. Among adults, 43% were overweight, and 16% were in the grip of obesity. Additionally, 37 million children under five were overweight, and over 390 million children and teenagers aged 5-19 years were overweight, including 160 million coping with obesity. Thus, escalating rates of obesity are fueling the growth of the gastric cancer market.

Get Your Gastric Cancer Market Report Here:
https://www.thebusinessresearchcompany.com/report/gastric-cancer-global-market-report

What growth opportunities are expected to drive the gastric cancer market's CAGR through 2034?
In recent times, the market size for gastric cancer has seen a rapid surge. Growth is projected to continue, increasing from $3.17 billion in 2024 to $3.65 billion in 2025, which represents a 15.4% compound annual growth rate (CAGR). This substantial growth is due to factors such as an escalating geriatric population, heightened healthcare consciousness, an increase in genetic mutations, a rising adoption of unhealthy lifestyles, and an enhanced awareness about cancer.

The market size of gastric cancer is projected to experience swift expansion in the upcoming years, reaching $6.43 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 15.2%. This surge during the forecast period can be accredited to factors such as rising obesity levels, amplified governmental efforts, escalating healthcare investments, increased demand for oral medications, and the growth in the number of cancer treatment centers. Key trends for the forecast period include the merging of chemotherapy treatments, product diversification, the implementation of robotic-assisted surgery, personalized therapies, strategic partnerships, as well as the employment of sophisticated diagnostic instruments.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20797&type=smp

What are the emerging trends shaping the future of the gastric cancer market?
The gastric cancer market is witnessing a focus on the development of cutting-edge solutions, such as companion diagnostic assays, by leading companies to promote personalized care. These companion diagnostic assays are tests designed to discover patients who would most profit from a specific treatment, depending on the detection of certain biomarkers. As an example, F. Hoffmann-La Roche Ltd., a Switzerland-based pharmaceutical firm, received approval from the U.S. Food and Drug Administration (FDA) for the VENTANA CLDN18 (43-14A) RxDx Assay in October 2024. This is the pioneer immunohistochemistry (IHC) companion diagnostic for assessing CLDN18 protein expression in gastric and gastroesophageal junction (GEJ) adenocarcinoma. The assay determines patients qualified for targeted treatment with VYLOY (zolbetuximab) by evaluating CLDN18 protein forms, mainly CLDN18.2. The test, conducted with the OptiView DAB IHC Detection Kit on the BenchMark ULTRA instrument, represents progress in personalized healthcare and paves the way for more treatment possibilities for gastric and GEJ adenocarcinoma.

Which growth-oriented segments of the gastric cancer market are leading the industry's development?
The gastric cancer market covered in this report is segmented -

1) By Type: Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Other Types
2) By Diagnosis: Endoscopy, Biopsy, Imaging Tests, Exploratory Surgery, Other Diagnosis
3) By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Palliative Care, Other Treatments
4) By Distribution Channel: Hospital Pharmacies, Specialty And Retail Pharmacies, Other Distribution Channels

Subsegments:
1) By Adenocarcinoma: Intestinal Type Adenocarcinoma, Diffuse Type Adenocarcinoma, Mixed Type Adenocarcinoma
2) By Lymphoma: Primary Gastric Lymphoma, Secondary Gastric Lymphoma
3) By Gastrointestinal Stromal Tumor (GIST): Primary GIST, Metastatic GIST
4) By Carcinoid Tumor: Gastric Carcinoid Type 1, Gastric Carcinoid Type 2, Gastric Carcinoid Type 3
5) By Other Types: Small Cell Carcinoma, Squamous Cell Carcinoma, Mixed Tumors

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20797

What regions are leading the charge in the gastric cancer market?
North America was the largest region in the gastric cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What companies are at the forefront of innovation in the gastric cancer market?
Major companies operating in the gastric cancer market are F. Hoffmann La Roche Ltd., Merck And Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Abbott Laboratories, Novartis AG, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Samsung Biologics Co. Ltd., Celltrion Healthcare Co. Ltd., Biocon Limited, Hanmi Pharmaceuticals, Mylan N.V., Taiho Oncology Inc., Hikma Pharmaceuticals PLC, Taiho Pharmaceuticals Co. Ltd., AROG Pharmaceuticals Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=20797&type=smp

What Is Covered In The Gastric Cancer Global Market Report?

•Market Size Forecast: Examine the gastric cancer market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the gastric cancer market for a structured understanding.
•Key Players Overview: Analyze major players in the gastric cancer market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the gastric cancer market.
•Segment Contributions: Evaluate how different segments drive overall growth in the gastric cancer market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the gastric cancer market.
•Industry Challenges: Identify potential risks and obstacles affecting the gastric cancer market.
•Competitive Landscape: Review strategic developments in the gastric cancer market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.